ClinicalTrials.gg
Active, not recruitingNCT07044362Updated Nov 12, 2026

Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis

An interventional study of HistoSonics Edison® System and Chemotherapy in Colorectal Cancer, Liver Metastases and Liver Cancer, sponsored by Case Comprehensive Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Case Comprehensive Cancer Center · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 12, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Colorectal Neoplasms by Case Comprehensive Cancer Center — 3 open to participants now, 4 under way, none of them phase 3. Colorectal Neoplasms · Case Comprehensive Cancer Center.

Started
2025
the only one that year
No phase
4 of 17
2 open now
Registered
16th of 17
by date

Among the 17 studies in Colorectal Neoplasms by Case Comprehensive Cancer Center, this one is the only one that started in 2025, is one of 4 with no phase, and was the 16th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 17 studies in Colorectal Neoplasms by Case Comprehensive Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Colorectal Neoplasms by Case Comprehensive Cancer Center, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if histotripsy plus chemotherapy works to treat unresectable, bilobar liver- confined colorectal cancer liver metastasis (CRLM). The main question this clinical trial aims to answer is:

  • Does the management of this condition with uninterrupted palliative chemotherapy and histotripsy demonstrate improved progression-free survival?

Participants will:

  • Receive chemotherapy treatment per standard procedure.
  • Undergo histotripsy treatment according to current standard procedures at Cleveland Clinic.
  • Occasionally receive Computerized Tomography (CT) scan with and without contrast, give biopsy of treated and untreated liver lesions, and participate in a blood draw of up to 3 teaspoons at each in-person visit.
  • Participate in genetic testing, as a part of the standard of care for the treatment.
Read the detailed description

This is a prospective trial testing the benefits of histotripsy plus chemotherapy for participants with colorectal liver metastasis. Histotripsy has been approved by the FDA with De Novo classification for non-invasive destruction of liver tumors. Up to 100 participants with colorectal cancer liver metastasis will be included.

03

Conditions studied

  • Colorectal Cancer
  • Liver Metastases
  • Liver Cancer

Keywords

  • Histotripsy
  • Liver-confined
  • Liver colorectal cancer liver metastasis
  • Liver-confined colorectal cancer liver metastasis
  • Chemotherapy
  • Advanced Colorectal
  • Advanced Colorectal Liver Metastasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with liver-confined colorectal cancer liver (CRLM) or participants who have low-volume pulmonary disease along with CRLM
  • Participants receiving therapy with base of 5-FU with either oxaliplatin or irinotecan, or who are within 3 months of beginning chemotherapy, or participants who have completed chemotherapy treatment within 1 month of the histotripsy evaluation
  • Participants who have undergone other liver-directed therapy, such as ablation, embolization
  • Participants with multiple unresectable metastases that cannot be completely treated with resection and/or ablation
  • Participants aged ≥18 years

Exclusion criteria

Exclusion Criteria:

  • Participants with resectable disease
  • Participants with non-pulmonary extra-hepatic disease including but not limited to bone or peritoneal .
  • Participants who are not able to tolerate general anesthesia
  • Participants who have Childs C Cirrhosis
  • Other non-skin within 2 years of study
  • WBC count \< 3,000 /uL
  • \< 1,500 /uL
  • History of Non-malignant serious concurrent illness that would increase the risk of histotripsy
  • Participants with MSI-High
  • Participants aged \< 18 years
  • Pregnant participants
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Histotripsy + Chemotherapy

    All enrolled participants will undergo combined treatment with Histotripsy and chemotherapy without interruption in the chemotherapy.

    Device: HistoSonics Edison® System · Drug: Chemotherapy

Interventions

  • DeviceHistoSonics Edison® System

    Histotripsy is a novel, totally non-invasive, non-ionizing, and non-thermal ablation technique that mechanically disrupts tumors through precisely controlled acoustic cavitation. Histotripsy is administered via HistoSonics Edison® System.

  • DrugChemotherapy

    Chemotherapy (standard of care with first line therapy of base of 5-FU with either oxaliplatin or irinotecan).

06

What researchers measure

Primary outcomes

  1. Radiologic tumor viability

    As assessed by the degree of short-term local tumor control in Colorectal Liver Metastasis(CRLM)

    Time frame: 90 days post-treatment

Secondary outcomes

  1. Rate of Tumor Necrosis

    Biopsy results will be used to assess the degree of tumor necrosis in treated lesions.

    Time frame: 30 days post-treatment

  2. Percentage of Viable Tumor in Lesion

    Biopsy results will be used to assess the percentage of lesions that have viable tumor.

    Time frame: 30 days post-treatment

  3. Infiltration of CD4

    Biopsy results will be used to assess the infiltration of CD4.

    Time frame: 30 days post-treatment

  4. Infiltration of CD8

    Biopsy results will be used to assess the infiltration of CD8.

    Time frame: Baseline, 30 days post-treatment

  5. Infiltration of B-cells

    Biopsy results will be used to assess the infiltration of B-cells.

    Time frame: 30 days post- treatment

  6. Infiltration of CD45

    Biopsy results will be used to assess the infiltration of CD45.

    Time frame: 30 days post-treatment

  7. Infiltration of CD68

    Biopsy results will be used to assess the infiltration of CD68.

    Time frame: 30 days post-treatment

  8. Infiltration of PD-1

    Biopsy results will be used to assess the infiltration of PD-1.

    Time frame: 30 days post-treatment

  9. Infiltration of PD-L1

    Biopsy results will be used to assess the infiltration of PD-L1.

    Time frame: 30 days after treatment

  10. Infiltration of CTLA-4

    Biopsy results will be used to assess the infiltration of CTLA-4.

    Time frame: 30 days post-treatment

  11. Overall Survival

    Median overall survival will be measured up to 2 years post treatment.

    Time frame: Up to 24 months post-treatment

  12. Progression Free Survival (PFS)

    The rate of progression free survival will be measured up to 2 years post treatment.

    Time frame: Up to 24 months post-treatment

  13. 30 day Complications

    The safety profile of the treatment, as measured by the complications at 30 days.

    Time frame: 30 days post-treatment

  14. 90 day Complications

    The safety profile of the treatment, as measured by the complications at 90 days.

    Time frame: 90 days post-treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — There is no need for sharing IPD for this clinical trial.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 12 months is below that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jun 30, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 12, 2026
Enrollment
100 (estimated)→2 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Active, not recruiting
    Enrollment 100 (estimated)→2 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07044362
Collaborators
HistoSonics, Inc.
Responsible party
Sponsor
First posted
Jun 30, 2025
Start date
Nov 19, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Federico Aucejo, MD
principal investigator · Cleveland Clinic, Digestive Disease Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion